Comparison of 3-Factor Prothrombin Complex Concentrate and Low-Dose Recombinant Factor VIIa for Warfarin Reversal

World Journal of Emergency Surgery

Robert M Roach⁴  Jeffrey Vespa²  Katherine E Hutson⁵  Nichole M Rupnow¹  Nada M Abou-Karam³  Eric D Irwin⁴  Scott A Chapman⁵ 

[1] Department of Pharmaceutical Care and Health Systems, University of Minnesota College of Pharmacy, Minneapolis, USA;Department of Emergency Medicine, North Memorial Medical Center, Minneapolis, USA;University of Minnesota College of Pharmacy, 5-130 Weaver-Densford Hall, 308 Harvard Street SE, Minneapolis, MN 55455, USA;Department of Trauma, North Memorial Medical Center, Robbinsdale, MN, USA;Department of Pharmacy Services, North Memorial Medical Center, Minneapolis, USA

关键词: Warfarin;    Recombinant factor VIIa;    Prothrombin complex concentrate;    Trauma;    Hemorrhage;    Anticoagulation;   

Others  :  791289
DOI  :  10.1186/1749-7922-9-27

 received in 2013-11-13, accepted in 2014-03-18,  发布年份 2014

【 摘 要 】

Introduction

Prothrombin complex concentrate (PCC) and recombinant Factor VIIa (rFVIIa) have been used for emergent reversal of warfarin anticoagulation. Few clinical studies have compared these agents in warfarin reversal. We compared warfarin reversal in patients who received either 3 factor PCC (PCC3) or low-dose rFVIIa (LDrFVIIa) for reversal of warfarin anticoagulation.

Methods

Data were collected from medical charts of patients who received at least one dose of PCC3 (20 units/kg) or LDrFVIIa (1000 or 1200 mcg) for emergent warfarin reversal from August 2007 to October 2011. The primary end-points were achievement of an INR 1.5 or less for efficacy and thromboembolic events for safety.

Results

Seventy-four PCC3 and 32 LDrFVIIa patients were analyzed. Baseline demographics, reason for warfarin reversal, and initial INR were equivalent. There was no difference in the use of vitamin K or fresh frozen plasma. More LDrFVIIa patients achieved an INR of 1.5 or less (71.9% vs. 33.8%, p =0.001). The follow-up INR was lower after LDrFVIIa (1.25 vs. 1.75, p < 0.05) and the percent change in INR was larger after LDrFVIIa (54.1% vs. 38.8%, p = 0.002). There was no difference in the number of thromboembolic events (2 LDrFVIIa vs. 5 PCC3, p = 1.00), mortality, length of hospital stay, or cost.

Conclusions

Based on achieving a goal INR of 1.5 or less, LDrFVIIa was more likely than PCC3 to reverse warfarin anticoagulation. Thromboembolic events were equivalent in patients receiving PCC3 and LDrFVIIa.

【 授权许可】

   
2014 Chapman et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Douketis JD, Arneklev K, Goldhaber SZ, Spandorfer J, Halperin F, Horrow J: Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk fact ors for bleeding. Ann Intern Med 2006, 166:853-859.
• [2]Riegert-Johnson DL, Volcheck GW: The incidence of anaphylaxis following intravenous phytonadione (vitamin K1): a 5-year retrospective review. Ann Allergy Asthma Immunol 2002, 89:400-406.
• [3]Walter A, Gallus AS, Ann W, Mark C, Hylek EM, Gualtiero P: Oral Anticoagulant Therapy: Antithrombotic Therapy and Prevention of Thrombosis 9th edition. American College of Chest Physicians Evidence Based Clinical Practice Guidelines. Chest 2012, 14(2):e44s-e88s.
• [4]Huttner HB, Schellinger PD, Hartmann M, Köhrmann M, Juettler E, Wikner J, Mueller S, Meyding-Lamade U, Strobl R, Mansmann U, Schwab S, Steiner T: Hematoma growth and outcome in treated neurocritical care patients with intracranial hemorrhage related to warfarin anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke 2006, 37:1465-1470.
• [5]Brody DL, Aiyagari V, Shackleford AM, Diringer MN: Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage. Neurocritical Care 2005, 2:263-267.
• [6]Goldstein JN, Thomas SH, Frontiero V, Joseph A, Engel C, Snider R, Smith EE, Greenberg SM, Rosand J: Timing of fresh frozen plasma administration and rapid correction of coagulopathy in warfarin-related intracerebral hemorrhage. Stroke 2006, 37:151-155.
• [7]Lee SB, Manno EM, Layton KF, Wijdicks EFM: Progression of warfarin-associated intracerebral hemorrhage after INR normalization with FFP. Neurology 2006, 67:1272-1274.
• [8]Siddiq F, Jalil A, McDaniel C, Brock DG, Pineda CC, Bell RD, Lee K: Effectiveness of Factor IX complex concentrate in reversing warfarin associated coagulopathy for intracerebral hemorrhage. Neurocrit Care 2008, 8:36-41.
• [9]Hall AB, Carson BC: Reversal of warfarin-induced coagulopathy: review of treatment options. J Emerg Nurs 2012, 38(1):98-101.
• [10]Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, Svensson PJ, Veenstra DL, Crowther M, Guyatt GH: Evidence-Based Management of Anticoagulant Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141(2):e152S-e184S. doi:10.1378/chest.11-2295
• [11]Leissinger CA, Blatt PM, Hoots WK, Ewenstein B: Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol 2008, 83:137-143.
• [12]Aiyagari V, Testai FD: Correction of coagulopathy in warfarin associated cerebral hemorrhage. Curr Opin Crit Care 2009, 15:87-92.
• [13]Dager WE, King JH, Regalia RC, Williamson D, Gosselin RC, White RH, Tharratt RS, Albertson TE: Reversal of elevated international normalized ratios and bleeding with low-dose recombinant activated factor VII in patients receiving warfarin. Pharmacotherapy 2006, 26:1091-1098.
• [14]Pinner NA, Hurdle AC, Oliphant C, Reaves A, Lobo B, Sills A: Treatment of warfarin- related intracranial hemorrhage: a comparison of prothrombin complex concentrate and recombinant activated factor VII. World Neurosurg 2010, 74:631-635.
• [15]Sarode R, Milling TJ Jr, Refaai MA, Mangione A, Schneider A, Durn BL, Goldstein JN: Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding. Circulation 2013, 128:1234-1243.
• [16]Holland L, Warkentin TE, Refaai M, Crowther MA, Johnston MA, Sarode R: Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose. Transfusion 2009, 49:1171-1177.
• [17]Imberti D, Barillari G, Biasiolo C, Bianchi M, Contino L, Duce R, D'Incà M, Gnani MC, Mari E, Ageno W: Emergency reversal of anticoagulation with a three-factor prothrombin complex concentrate in patients with intracranial hemorrhage. Blood Transfus 2011, 9:148-155.
• [18]Markis M, van Veen JJ: Three of four factor prothrombin complex concentrate for emergency anticoagulation reversal. Blood Transfus 2011, 9:117-119.
• [19]Lin J, Hanigan WC, Tarantino M, Wang J: The use of recombinant activated factor VII to reverse warfarin-induced anticoagulation in patients with hemorrhages in the central nervous system: preliminary findings. J Neurosurg 2003, 98:737-740.
• [20]Freeman WD, Brott TG, Barrett KM, Castillo PR, Deen HG Jr, Czervionke LF, Meschia JF: Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. Mayo Clin Proc 2004, 79:1495-1500.
• [21]Ilyas C, Beyer GM, Dutton RP, Scalea TM, Hess JR: Recombinant factor VIIa for warfarin associated intracranial bleeding. J Clin Anesth 2008, 20:276-279.
• [22]Roitberg B, Emechebe-Kennedy O, Amin-Hanjani S, Mucksavage J, Tesoro E: Human recombinant factor VII for emergency reversal of coagulopathy in neurosurgical patients: a retrospective comparative study. Neurosurgery 2005, 57:832-836.
• [23]Grifols Biologicals Inc.: Profilnine® SD (Factor IX Complex) package insert. Los Angeles, CA; 2010.
• [24]Skolnick BE, Mathews DR, Khutoryansky NM, Pusateri AE, Carr ME: Exploratory study on the reversal of warfarin with rFVIIa in healthy subjects. Blood 2010, 116:693-701.
• [25]Dickeite G: Prothrombin complex concentrate versus recombinant factor VIIa for reversal of coumarin anticoagulation. Thromb Res 2007, 119:643-651.
• [26]Safauoi MN, Aazami R, Hotz H, Wilson MT, Margulies DR: A promising new alternative for the rapid reversal of warfarin coagulopathy in traumatic intracranial hemorrhage. Am J Surg 2009, 197:785-790.
• [27]Warren O, Simon B: Massive, fatal, intracardiac thrombosis associated with prothrombin complex concentrate. Ann Emerg Med 2009, 53:758-761.
• [28]Levi M, Levi JH, Anderson HF, Truloff D: Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010, 363:1791-1800.